Analyst Price Targets — TYRA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 14, 2026 8:14 pm | Brad Canino | Guggenheim | $54.00 | $35.27 | TheFly | Tyra Biosciences initiated with a Buy at Guggenheim |
| February 17, 2026 11:12 am | Mitchell Kapoor | H.C. Wainwright | $45.00 | $27.99 | TheFly | Tyra Biosciences price target raised to $45 from $30 at H.C. Wainwright |
| February 13, 2026 2:03 pm | Robert Driscoll | Wedbush | $53.00 | $30.10 | TheFly | Tyra Biosciences price target raised to $53 from $37 at Wedbush |
| February 3, 2026 1:04 pm | — | Oppenheimer | $50.00 | $31.72 | TheFly | Tyra Biosciences price target raised to $50 from $36 at Oppenheimer |
| January 27, 2026 9:30 pm | — | Barclays | $59.00 | $31.40 | TheFly | Tyra Biosciences initiated with an Overweight at Barclays |
| January 23, 2026 11:59 am | — | Piper Sandler | $42.00 | $30.91 | TheFly | Tyra Biosciences price target raised to $42 from $33 at Piper Sandler |
| December 16, 2025 11:20 am | Robert Driscoll | Wedbush | $37.00 | $22.11 | TheFly | Wedbush raises price target on Tyra Biosciences, adds to Best Ideas List |
| September 10, 2025 11:03 am | Matthew Biegler | Oppenheimer | $36.00 | $12.18 | TheFly | Tyra Biosciences price target raised to $36 from $30 at Oppenheimer |
| November 11, 2024 12:23 pm | Mitchell Kapoor | H.C. Wainwright | $30.00 | $16.70 | StreetInsider | Tyra Biosciences (TYRA) PT Lowered to $30 at H.C. Wainwright |
| October 18, 2024 6:06 am | Jason Zemansky | Bank of America Securities | $31.00 | $25.98 | StreetInsider | BofA Securities Upgrades Tyra Biosciences (TYRA) to Buy |
Latest News for TYRA
-Seasoned biopharmaceutical leader brings deep commercial and strategic expertise to support TYRA's next phase of growth- CARLSBAD, Calif., April 17, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the…
Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) Director Gilla Kaplan sold 14,295 shares of the firm's stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $36.97, for a total value of $528,486.15. Following the transaction, the director directly owned 28,231 shares of the company's
Boone Capital added 398,482 shares of TYRA in the fourth quarter. The quarter-end position value rose by $10.48 million as a result of the new stake.
- Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications - - Interim Ph2 data readouts on track: SURF302 expected by end of 1H'26 and BEACH301 in 2H '26 - - Cash, cash equivalents and marketable securities of $256.0 million at Q4 2025; runway through at least 2027 - CARLSBAD, Calif., March 2, 2026 /PRNewswire/ -- Tyra…
CARLSBAD, Calif., Feb. 23, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that two abstracts have been accepted for presentation at the 2026 ASCO® Genitourinary (GU) Cancers Symposium (ASCO GU).
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TYRA.
U.S. House Trading
No House trades found for TYRA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.